Temozolomide (CCRG 81045)

For research use only.

Catalog No.S1237 Synonyms: NSC 362856,TMZ

113 publications

Temozolomide (CCRG 81045) Chemical Structure

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) GBP 64 In stock
GBP 57 In stock
GBP 139 In stock
GBP 712 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Temozolomide (CCRG 81045) has been cited by 113 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NUL6UXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fONFQ5KGh? Mk\XTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
KellyCis83 NG\LcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYntd|RZPDhiaB?= NVLtWZQzUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>? NGHI[pQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFI5Oid-MkW5OlAzQDJ:L3G+
SK-N-AS MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPrS4pbPDhiaB?= M2Xu[WlEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0> M2nvNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
SK-N-ASCis24 NULBSZk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[0PEBp MYHJR|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=> NXXS[4xNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
CHP-212 M4rTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX76XnRWPDhiaB?= M3i0TGlEPTB;Nz65O-KBkcLz4pEJNE43QSEQvF2= MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
CHP-212Cis100 NHe4TWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK3eIh4PDhiaB?= MVvJR|UxRTlwNUZihKnDueLCiUCuPFgh|ryP Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
U87  NFHtbZZHfW6ldHnvckBCe3OjeR?= NYH0Z2hzOTByIN88US=> MlvmNlQuPzJiaB?= NV7yOpNKcW6mdXPld{BF[1JzIHX4dJJme3Orb36= MojjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEi4OlgoRjJ3OEC4PFY5RC:jPh?=
LN229 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUewMVUxKM7:TR?= M{f5c2lEPTB;MU[g{txO MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEK3N{c,OjV5NUCyO|M9N2F-
TR-LN229 M3zKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKwMVUxKM7:TR?= M3zrZWlEPTB;N{eg{txO M1XNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwNlc{Lz5{NUe1NFI4OzxxYU6=
U87  NVTNZWN5SXCxcITvd4l{KEG|c3H5 M3[5V|DjiJN{MEFihKnDvU1? MXiyOEBp NGTaXXFmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? M4PrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkixOlY5Lz5{NU[4NVY3QDxxYU6=
U251MG MUDBdI9xfG:|aYOgRZN{[Xl? MV:xNFDDqM7:TR?= NYPKd21GPDhiaB?= MWrQRnM> MmrabY5lfWOnczDhdI9xfG:|aYO= NULoOnkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFA1PjRpPkK1OlgxPDZ2PD;hQi=>
U87MG M{GwPWFxd3C2b4Ppd{BCe3OjeR?= MYSxNFDDqM7:TR?= MnfkOFghcA>? MUXQRnM> NVv2NoQ{cW6mdXPld{BieG:ydH;zbZM> M{XnSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkiwOFY1Lz5{NU[4NFQ3PDxxYU6=
U87 NHXIRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXznN|FxPTBvM{WwJO69VQ>? M17aSVQ5yqCqwrC= MWTpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> M{joWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
U118  MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P5cFUxNTN3MDFOwG0> NIHQWIE1QMLiaNMg NIDnenFqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? Ml7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U87 NUnhWGNkTnWwY4Tpc44hSXO|YYm= NFPzVVYzPTBxM{WwJO69VQ>? MUm0POKhcMLi Mn;F[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U118  MmL0SpVv[3Srb36gRZN{[Xl? MWiyOVAwOzVyIN88US=> M1TWWlQ5yqCqwrC= NWX3fmFK\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn NUjkO3lSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVQzOjNpPkK1OVU1OjJ|PD;hQi=>
U87 NUDteWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PGNFI2OC9|NUCg{txO Mki3OFjDqGkEoB?= NHrrXoVqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
A375 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDyVWw1QMLiaNMg MnvYTWM2OD1{NkWg{txO Ml7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
A2058 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;PRlQ5yqCqwrC= MX;JR|UxRTF{IN88US=> M4TveFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK0OVUzLz5{NUWyOFU2OjxxYU6=
M238 M2Tad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljFOFjDqGkEoB?= M1PoWmlEPTB;NECg{txO Mmf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M249 M{TPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36zTFQ5yqCqwrC= M13He2lEPTB;MkW0JO69VQ>? M3\GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK0OVUzLz5{NUWyOFU2OjxxYU6=
M21 M2\B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO0POKhcMLi Mm\OTWM2OD1{MkGg{txO MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
U251 Ml3HR5l1d3SxeHn0fUBCe3OjeR?= MoD1NlAh|ryPwrC= MljuOFjDqGkEoB?= MYTy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm NFfPNW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFM5OSd-MkW0N|Q{QDF:L3G+
LN229 MUTDfZRwfG:6aYT5JGF{e2G7 NEDSbmQzOCEQvF5CpC=> NWHyOZYxPDkEoHlCpC=> MU\y[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm NX;wNotbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|Q{QDFpPkK1OFM1OzhzPD;hQi=>
U373MG-LUC MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17IXlczKGh? NX;mPJVnUUN3ME62NFAh|ryP MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{G5OVMoRjJ3NEOxPVU{RC:jPh?=
U87  NVvIdYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTTSXFuOjVvMkCwJO69VQ>? M3uwblQ5yqCqwrC= NITOUItqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyMEe0OUc,OjV2MEC3OFU9N2F-
U251 NX;FPJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCyOU0zODBizszN MWe0POKhcMLi NXjOZ3p7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEC3OFUoRjJ3NECwO|Q2RC:jPh?=
U251 NVTjblRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPwVJUyODBvNECwJO69VQ>? NHXGOWw4Oi97NjDo MXT0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? MlzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|N{WyO|EoRjJ3M{e1NlcyRC:jPh?=
U373 NEP0OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nWZ|ExOC12MECg{txO M1XseFczNzl4IHi= NXzkSGZ[fGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg M13JNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e1NlcyLz5{NUO3OVI4OTxxYU6=
U343 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e4ZVExOC12MECg{txO Ml7FO|IwQTZiaB?= NFjSfIR1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= M{PrNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e1NlcyLz5{NUO3OVI4OTxxYU6=
U87MG-luc2 M3SyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHVNVAxNTRyMDFOwG0> MVi3Nk86PiCq MUf0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NF7aZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO|UzPzF:L3G+
U87 MWPGeY5kfGmxbjDBd5NigQ>? NGf4dFYzODBizszN NFjwToQ1QCCq Mn:wbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? M1XIbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O|IyLz5{NUOzO|czOTxxYU6=
U251 MlTJSpVv[3Srb36gRZN{[Xl? NGnnW2kzODBizszN NUTnUZlTPDhiaB?= M2ixc4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? NIjLPYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO|czOSd-MkWzN|c4OjF:L3G+
A172 MkTkSpVv[3Srb36gRZN{[Xl? MWiyNFAh|ryP M37kelQ5KGh? MYrpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NU\GcHh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U251 MV7GeY5kfGmxbjDBd5NigQ>? MXOyNFAh|ryP M4fLTVQ5KGh? M1f2OIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? MnvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{e3NlEoRjJ3M{O3O|IyRC:jPh?=
A172 NXvsTmZiTnWwY4Tpc44hSXO|YYm= MYGyNFAh|ryP NV\qZoR1PDhiaB?= MkXIbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{e3NlEoRjJ3M{O3O|IyRC:jPh?=
U87 NVnIO|JoTnWwY4Tpc44hSXO|YYm= MXKyNFAh|ryP MoKzNlQwPzJxMUKwJIg> MnLHbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 NH33UHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO|czOSd-MkWzN|c4OjF:L3G+
U251 NIHPZnZHfW6ldHnvckBCe3OjeR?= MmDsNlAxKM7:TR?= MnXKNlQwPzJxMUKwJIg> NVP0O|BzcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 NXjGT|hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
A172 M4XieGZ2dmO2aX;uJGF{e2G7 NGG5UmszODBizszN NVPqcIE4OjRxN{KvNVIxKGh? NHnQXHVqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? M1f5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O|IyLz5{NUOzO|czOTxxYU6=
SNB19V MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfSO{Bl NInweWFFVVOR NWXCVohrT0l3ME2zOU44yrFzMjFOwG0> NUXjfoY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19M NVPwWXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG2cYg4KGR? NYPieoxZTE2VTx?= MVLHTVUxRTR4OT65xtE5QCEQvF2= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
SNB19VR M2O0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6ySnFRPyCm NX\tSI1kTE2VTx?= NW\XbGtJT0l3ME2yPFAvOsLzMUig{txO M{DMW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
U373V MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTOU|k4KGR? MkH1SG1UVw>? NIjSS4tIUTVyPU[4MlDDuTN{IN88US=> M3HHPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
U373M MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fKTlch\A>? M2DFOmROW09? NXO3bXFHT0l3ME2zOlgvP8LzOE[g{txO NF;Pb|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q1OSd-MkWyO|c1PDF:L3G+
U373VR NUXxNXhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTL[YFLPyCm MWLEUXNQ NFjaOoJIUTVyPUK4PE45yrF|MzFOwG0> M1n1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
U87MG M3;TZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTrO{Bl MW\EUXNQ MYHHTVUxRTN6LkRCtVIxKM7:TR?= NFXpWHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q1OSd-MkWyO|c1PDF:L3G+
HCT116 NXH5TGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e1R|ch\A>? NFjOd2VFVVOR NHftWIJIUTVyPUW3PU46yrF|MjFOwG0> NIfDUIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q1OSd-MkWyO|c1PDF:L3G+
DLD1 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXKO{Bl M4e3Z2ROW09? NUDsUJl6T0l3ME21NFEvPMLzOUOg{txO NXHHbZJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
MRC5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTOO{Bl NUHZNpNoTE2VTx?= MYjHTVUxRTR2OT60xtE5KM7:TR?= NX3xSolZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19V  M{j0TGZ2dmO2aX;uJGF{e2G7 NGrLflgyODBizszNxsBVVVp? MVqwMVczKGh? MkfTbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
T98G  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:1M|ExNzF3IN88US=> MX:yOOKhcA>? M2f2Rolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U251  NHi4cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy1M|ExNzF3IN88US=> M1Ttd|I1yqCq MUjpcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= NXPpfFRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
T98G  NHKxTm9HfW6ldHnvckBCe3OjeR?= MorRNVUh|ryP NEXoSmkzPMLiaB?= MkDqbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U251  MXzGeY5kfGmxbjDBd5NigQ>? MmnMNVUh|ryP M4TnOVI1yqCq MnjBbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U-87 MG NFvDW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvReoc4OiCq M{H0dWlEPTB;MD65N{BuVcLi MnPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEWzN|IoRjJ3MkS1N|MzRC:jPh?=
U-118 MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LIOFczKGh? MojtTWM2OD1zLkC1JI1OyqB? M4[2c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkS1N|MzLz5{NUK0OVM{OjxxYU6=
U87 M1WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKyOEBp MoL3TWM2OD1{NkCuN|Qh|ryPwrC= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5M{KzN{c,OjVzN{OyN|M9N2F-
U87 GSLCs MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[yOEBp NY\yZYE1UUN3ME23OlYvOTFizszNxsA> NXH2[VlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO|MzOzNpPkK1NVc{OjN|PD;hQi=>
U87MG NUjzfIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwO|IhcA>? NVPJSHNIUUN3ME2xOU43OjVizszNxsA> NVPSUoVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVA6OTVpPkK1NFUxQTF3PD;hQi=>
U251 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnoNVAxNTRyMDFOwG0> NGXlOFM1QCCq MYLEUXNQ Ml3PbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF7VWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yN|c{Pid-MkS2NlM4OzZ:L3G+
U87 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\lNVAxNTRyMDFOwG0> MofBOFghcA>? M4[1OWROW09? MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
MDA-MB-231-br M3T0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\sbIt7OC1zMDFOwG0> M2C0SVQ5KGh? M3Szd2ROW09? NWDldHlIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N|Y9N2F-
HCC-1937 NH;UdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzoSlQxNTNyMDFOwG0> NGLleIk1QCCq NWjN[2o6TE2VTx?= MnjPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4m5e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
MDA-MB-231 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmwMVQxKM7:TR?= Ml;0OFghcA>? MXXEUXNQ M1zlWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1Xv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
MDA-MB-468 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDwSXYxNTVyMDFOwG0> NVfPfINkPDhiaB?= MkDDSG1UVw>? NXLhflE2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWLERXdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
T47D NXX6SmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMVExOCEQvF2= NFznepg1QCCq M2HrbmROW09? M4HaT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1fPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
MCF7 M4XJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LhOVAuOTByMDFOwG0> M1W3fFQ5KGh? MXfEUXNQ NIjQfHNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N|Y9N2F-
Hs683 NW\MUXhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ZNE0yODByIN88US=> M{Xmdlk3KGh? M1viPWlEPTB;MUK4Mlkh|ryP NF\ucpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVkxPyd-MkS0PVU6ODd:L3G+
U87 NYDLR5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G4eFAuOTByMDFOwG0> MkTDPVYhcA>? M{PwbWlEPTB;MUiuOFUh|ryP NIjMUYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVkxPyd-MkS0PVU6ODd:L3G+
LNZ308 NEf3XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTleZg3OC1zMECwJO69VQ>? MUi5OkBp M3\EOGlEPTB;M{K2Mlch|ryP Mmr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUW5NFcoRjJ2NEm1PVA4RC:jPh?=
U87 MXLBdI9xfG:|aYOgRZN{[Xl? MVmxNFAh|ryP MnLpOFghcA>? NWOzSnF5TE2VTx?= M3jsXIlv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= M4\pdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEixOVg3Lz5{NES4NVU5PjxxYU6=
U251  Ml3mRZBweHSxc3nzJGF{e2G7 MYexNFAh|ryP NXHCWGJsPDhiaB?= MVjEUXNQ MU\pcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 NF;0VmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4NVU5Pid-MkS0PFE2QDZ:L3G+
U251 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmyOEBp MX;JR|UxRTh4LkK55qCKyrIkgJmxMlU5KM7:TR?= NWS1eGxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlY6PTRpPkK0N|I3QTV2PD;hQi=>
U251 NXK5OVhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3EOFghcA>? NITVOZFKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR|Mk[5OVQ9N2F-
U251 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\DXJE4OiCq NUKyfVVGUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> MmDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
U251 NU\tbFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjMNpBxQTZiaB?= NX;iNHhTUUN3ME22PU45OuLCidMx5qCKOy5yNDFOwG0> MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
T98G NX:5V5FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3MNE04PTBizszN M1LaUlczNzl4IHi= Mm\abY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGniOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFA5OCd-MkSzNlQxQDB:L3G+
U251-MG MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTjfVZ7OC16MECg{txO M4PmbVczKGh? M{L2dIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO2N|AoRjJ2MEmzOlMxRC:jPh?=
D54-MG M4rX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\MbVQyOC16MECg{txO M3i5OFczKGh? M4H2Z4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO2N|AoRjJ2MEmzOlMxRC:jPh?=
SHG-44 NEnCSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqNVAuOjByIN88US=> NFjMXJY6PiCq M3T5Z2lEPTB;OT63N{DDuSB{LkGyJO69VQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373  NFnKblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr2OYlFOTBvMkCwJO69VQ>? NY\2fGpFQTZiaB?= Ml3rTWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
HT-29  NYL3OodDTnWwY4Tpc44hSXO|YYm= NX\w[nB2PTByIN88US=> M3LwdVI1NzR6IHi= Mn3N[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? NXT1Omx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN|gxPjhpPkK0NFM5ODZ6PD;hQi=>
PC-3  M4nxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nCOFAuOjVizszN MXS0PEBp MV3pcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> Mm\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NE[5N|QoRjJ|N{S2PVM1RC:jPh?=
PC-3  NGDERlNCeG:ydH;zbZMhSXO|YYm= MYCyOUDPxE1? M4LQd|Q5KGh? MkLEbY5lfWOnczDhdI9xfG:|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l NGrqS209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0Olk{PCd-MkO3OFY6OzR:L3G+
T98G MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfaOVAuPDByIN88US=> NWjG[2ViOTR2IHi= M1TKSolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzNUS5PUc,OjN5MUW0PVk9N2F-
U87-MG M1\YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P1NFExOCEEtV2= NWPveVJKPzJiaB?= NUfKWoFIcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
U251-MG Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLWOVAxOTByINM1US=> NXvFRpkyPzJiaB?= NFrKO4dqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
LNT-229 NYTDUHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzISGFlOy1zMECg{txO MWmyOEBp MoXtbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NW\mfIVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olc3OzJpPkKzOlY4PjN{PD;hQi=>
T98G NH70XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DJ[FExNTdyMDFOwG0> M{jMUFI1KGh? M3\CN4lvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mm\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N|IoRjJ|Nk[3OlMzRC:jPh?=
U87  NF\O[JFHfW6ldHnvckBCe3OjeR?= M3jZeVExOCEEtV2= Ml\HN{Bp NI[3WI9mdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>? M{\uN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nk[3OFY6Lz5{M{[2O|Q3QTxxYU6=
HCT116 NUDHOZJyTnWwY4Tpc44hSXO|YYm= MYCxNFAhyrWP Mn60N{Bp NWjocVBycW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= NEfPVIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2O|Q3QSd-MkO2Olc1Pjl:L3G+
HCT3-6 NIm4VFFHfW6ldHnvckBCe3OjeR?= MUixNFAhyrWP MUGzJIg> NHLHb4VqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= NX;RcGI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olc1PjlpPkKzOlY4PDZ7PD;hQi=>
U-87  NGLxRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXmco0xNTRyIN88US=> NHrjUlEyOiCm M4T6PIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87  NIG4VmZCeG:ydH;zbZMhSXO|YYm= MWmwMVQxKM7:TR?= NH7VdI8{NzZiZB?= M1znd4lv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M1rCOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkS1O|I6Lz5{M{[0OVczQTxxYU6=
U-87  MnLZSpVv[3Srb36gRZN{[Xl? NHXtdVIxNTRyIN88US=> MUCzM|Yh\A>? NXTyVW02cW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQ[lQh\A>? NXL0ZVF3UUN3ME2yNlYh|ryP NHTKbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
GB-SCC026 M4LFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu0JIQ> NFnubIdKSzVyPUWzMlEh|ryP NVvI[ItFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
GB-SCC028 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWxOEBl MmfjTWM2OD1zNkeg{txO MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUK3OVUoRjJ|NkGyO|U2RC:jPh?=
U87 NV70T4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm3dWh4PCCm Ml6xTWM2OD12NT6yJO69VQ>? NG[1c2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
U87 stem cell MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP1SZI1KGR? NWrmXGppUUN3ME22Ok44KM7:TR?= NEj2VGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
TLX5 lymphoma MXTDfZRwfG:6aXPpeJkh[XO|YYm= NIDTeG9KSzVyIE2gOUDPxE1? NX7aVmhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
GM892 A M{[wTWN6fG:2b4jpZ4l1gSCjc4PhfS=> NInrb5BKSzVyIE2gO{43KM7:TR?= NUPQXlhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
TLX5 lymphoma NVjsdFV4S3m2b4TvfIlkcXS7IHHzd4F6 M3TzNGlEPTBiPTC1JO69VQ>? M2rj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEW5NFE1Lz5zMkS1PVAyPDxxYU6=
HCT116 NIDxN29EgXSxdH;4bYNqfHliYYPzZZk> MnHlOEBl[Xm| M2WyOWlEPTBiPTC0MlM1KM7:TR?= M1n2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OECwPFA{Lz5zOUiwNFgxOzxxYU6=
SNB75 M4ixeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFmzN|cyOCC3TR?= M4jnSlI1KGi{cx?= M2PyO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17CO|Uh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?= M1SwUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVI3Lz5{MkK2PFUzPjxxYU6=
C6 M1yyZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFPNTokyODBidV2= M3fIflQ5KGi{cx?= MojCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDyZZQhSzZiY3XscJMh[XRiMUCwJJVOKGGodHXyJFQ5KGi{czDifUBv\XW2cnHsJJJm\CCrbnPvdpBwemG2aX;uJIF{e2G7 NHjnNGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFUzPid-MkKyOlg2OjZ:L3G+
SF295 MkHSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYOxNEB2VQ>? MX[yOEBpenN? MlTGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVRkK5OUBk\WyuczDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliU2LCJIF{e2G7 M4\XelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVI3Lz5{MkK2PFUzPjxxYU6=
U87 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NEfpepI2KGSjeYO= NE\kXWhKSzVyIE2gOFkh|ryP MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZyOEO4PUc,OjJ4MEizPFk9N2F-
U138MG MnGyR5l1d3SxeHnjbZR6KGG|c3H5 MXO0PEBpenN? NHG3NpZKSzVyIE2gNlYh|ryP NEfxemg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
C6 MVHDfZRwfG:6aXPpeJkh[XO|YYm= Ml7IOFghcHK| NWi4XZF7UUN3MDC9JFM1KM7:TR?= NELPW|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
A2780 M3;OV2FvfGm2dX3vdkBie3OjeR?= NU\BUJhyPSCmYYnz NHPCN4dKSzVyIE2gPE42KM7:TR?= MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ|OEm1OlIxRC:jPh?=
A2058 MoXVRY51cXS3bX;yJIF{e2G7 MWC1JIRigXN? NVntNpNNUUN3MDC9JFM2NjVizszN Ml\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ|OEm1OlIxRC:jPh?=
SNB19 Mn7GRY51cXS3bX;yJIF{e2G7 NY\BTmhJPSCmYYnz MkHZTWM2OCB;IEO3JO69VQ>? NIXYT|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5OVYzOCd-MkO4PVU3OjB:L3G+
M8 NYfDZ2dCSXCxcITvd4l{KGG|c3H5 M2[0dFUxKHSxIEGwNEB2VQ>? M13wSFQ5KGi{cx?= NFjtOXdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIF24JINmdGy|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEA2OCC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KEGSQz3sZYJmdGWmIHHucoV5cW5iVjDhcoQhPy2DQVSgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{ Mnq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O|coRjJ2MUK1PFc4RC:jPh?=
SK-MEL-30 NUPNPYE3SXCxcITvd4l{KGG|c3H5 NWDQWZByOTByIIXN MnrJOFghcHK| MlKzTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVSz3NSWwuOzBiY3XscJMh[XO|ZYPz[YQh[XNiYYDvdJRwfGmlL37lZ5JwfGmlIHPlcIx{KGG2IEGwNEB2VSCjZoTldkA1QCCqcoOgZpkhSVCFLXzhZoVt\WRiYX7u[ZhqdiCYIHHu[EA4NUGDRDDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMhemWuYYTpeoUhfG9iY3;ueJJwdA>? NGDYbHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
SK-MEL-30 M1nmXGFxd3C2b4Ppd{Bie3OjeR?= NVPGTo97PTBidV2= MkWyOFghcHK| NVH6fFUxUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy|IHH0JFUxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u NGfEVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1 Mo\QRZBweHSxc3nzJIF{e2G7 M1XycFExOCC3TR?= NY\xfJduPDhiaILz MoLETY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPTmSxJINmdGy|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEAyODBidV2gZYZ1\XJiNEigbJJ{KGK7IFHQR{1t[WKnbHXkJIFvdmW6aX6gWkBidmRiNz3BRWQhe3SjaX7pcocu[mG|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|IILlcIF1cX[nIITvJINwdnS{b3y= NH23cG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1 MX3BdI9xfG:|aYOgZZN{[Xl? M{H0TVUxKHWP MX20PEBpenN? M2nxU2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTV7UNUBk\WyuczDhd5Nme3OnZDDhd{BieG:ydH;0bYMwdmWlcn;0bYMh[2WubIOgZZQhPTBidV2gZYZ1\XJiNEigbJJ{KGK7IFHQR{1t[WKnbHXkJIFvdmW6aX6gWkBidmRiNz3BRWQhe3SjaX7pcocu[mG|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|IILlcIF1cX[nIITvJINwdnS{b3y= NH3RXnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
A2780 NWLIdnhNS3m2b4TvfIlkcXS7IHHzd4F6 M{nPSFUh\GG7cx?= MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC1JIRigXNiYomgUXRVKGG|c3H5 MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC0NVgoRjJ2OUCwOFE5RC:jPh?=
A2780/CP70 MnTTR5l1d3SxeHnjbZR6KGG|c3H5 NVG2XG9JPSCmYYnz MkD5R5l1d3SxeHnjbZR6KGGpYXnud5QhVU2ULXTl[olkcWWwdDDoeY1idiCDMke4NE9EWDdyIHPlcIx{KGGodHXyJFUh\GG7czDifUBOXFRiYYPzZZk> NYHlSYlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA1OThpPkK0PVAxPDF6PD;hQi=>
GBM 047T NIroRWhCdnSrdIXtc5Ih[XO|YYm= MYGyNEB2VQ>? NU[0fWVHOSC2bzCyJJdm\Wu| NHPVVoJVfW2xcnnjbYRidCCnZn\lZ5QhcW5icHH0bYVvfCCmZYLpeoVlKEeETTCwOFdVKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDu[ZVzd3OyaHXy[UBnd3KvYYTpc44h[XRiMkCgeW0h[W[2ZYKgNUB1dyB{IIfl[Yt{KGK7IEPEJJR2dW:{IHPsc45w\2WwaXOgZZN{[Xl? MoHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUW1N|IoRjJ4M{W1OVMzRC:jPh?=
GBM 464T NIH2RnBCdnSrdIXtc5Ih[XO|YYm= NEiyU5UzOCC3TR?= NVXn[m9tOSC2bzCyJJdm\Wu| NF;MXVRVfW2xcnnjbYRidCCnZn\lZ5QhcW5icHH0bYVvfCCmZYLpeoVlKEeETTC0OlRVKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDu[ZVzd3OyaHXy[UBnd3KvYYTpc44h[XRiMkCgeW0h[W[2ZYKgNUB1dyB{IIfl[Yt{KGK7IEPEJJR2dW:{IHPsc45w\2WwaXOgZZN{[Xl? NXjacI1uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVU2OzJpPkK2N|U2PTN{PD;hQi=>
U87MG M3H0bWZ2dmO2aX;uJIF{e2G7 MYKzJIhzew>? M4DJdmlv\HWldHnvckBw\iCGTlGgZYxsgWyjdHnvckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBPPy2PZXTHJIZwem2jdHnvckBi\nSncjCzJIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZzNESxOEc,Ojd4MUS0NVQ9N2F-
U87MG MYjBcpRqfHWvb4KgZZN{[Xl? MoPWRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgc5J1cG:2b4DpZ4FtdHlieHXuc4dz[W[2ZXSgbY4hUGG{bHHuJI52\GVibX;1d4Uh[nKjaX6gZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIIPsc5chfHWvb4Kg[5Jwf3SqIHH0JFUxKHWvb3yvb4ctKGm4IHHkcYlvcXO2ZYLl[EBwdmOnIHThbYx6KG[xcjC1JIRigXN? NG\zPHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[xOFQyPCd-Mke2NVQ1OTR:L3G+
U87MG NG\scGdCdnSrdIXtc5Ih[XO|YYm= M2LTUmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJI9zfGixdH;wbYNidGy7IIjlco9oemGodHXkJIlvKEijcnzhckBvfWSnIH3veZNmKGK{YXnuJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIH3veZNmKHO3co\peoFtKGG2IEWwJJVud2xxa3esJIl3KGGmbXnubZN1\XKnZDDvcoNmKGSjaXz5JIZweiB3IHThfZM> NX7XOXQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
MDCK NWjmfVl3S3m2b4TvfIlkcXS7IHHzd4F6 NF\LeGgzPCCqcoO= NHHiRYZEgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?= MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O|koRjJ5OEKzPFc6RC:jPh?=
MDCK NHnz[mVEgXSxdH;4bYNqfHliYYPzZZk> NESyeW8zPCCqcoO= NV3kWnFrS3m2b4TvfIlkcXS7IHHnZYlve3RiTVTDT{Bk\WyuczDlfJBz\XO|aX7nJINiemKxbnnjJIFvcHmmcnHz[UA6KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{Bu\WG|dYLl[EBi\nSncjC3JIRigXNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?= MmjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O|koRjJ5OEKzPFc6RC:jPh?=
NB-EBc1 NFPxVYhyUFSVIHHzd4F6 NXq5eFRTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> M2jLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
C6 NULQTohjS3m2b4TvfIlkcXS7IHHzd4F6 MY[0JIRigXN? MV;FR|UxKD1iMU[uOUDPxE1? NFW2ZZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
U87 M1TBc2N6fG:2b4jpZ4l1gSCjc4PhfS=> M4W5e|czKGi{cx?= M1\lWmlEPTBiPTCxPU4{QCEQvF2= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4NVAwLz6FaFXNRmw9N2F-
SNB19 MlPxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXz3WJVEPyCmYYnz Ml\aS2k2OCB;IEO1Mlch|ryP M2XzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
SNB19 Mki0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGX5OGc4KGSjeYO= NY\hXotCT0l3MDC9JFQ2NjZizszN M3jSNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
U373 NH3NTYxHfW6ldHnvckBie3OjeR?= M2XC[|ExOCC3TR?= MoHEO|IhcHK| NW\C[oVrUW6mdXP0bY9vKG:oIHTveYJt\SC|dILhcoRm\CCGTlGgZpJm[WtiaX6g[Y1xfHlidnXjeI9zKHS{YX7z[oVkfGWmIHj1cYFvKFV|N{OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h\2GvbXGtTFJCYCCuZY\lcEBifCBzMECgeW0h[W[2ZYKgO|IhcHK|IHL5JIZtd3diY4n0c41mfHK7 NEXRc3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
Glioma NYLBT5NNSW62aYT1cY9zKGG|c3H5 M{H1TWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGhwdW9ic3HwbYVveyBqaIXtZY4qKEeuaX;tZUBk\WyuczD4[Y5w\3KjZoTl[EBqdiC2cnHud4dmdmmlIH3veZNmKGG|c3Xzd4VlKGG|IH3veZNmKHO3co\peoFt MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms NSC 362856,TMZ
Smiles CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04091503 Not yet recruiting Drug: Intranasal Modified Temozolomide Glioma Malignant|Gliosarcoma|Astrocytoma of Brain Center Trials & Treatment Europe December 10 2019 Phase 1
NCT03932981 Recruiting Drug: Temozolomide Adult Brainstem Glioma Assistance Publique - Hôpitaux de Paris July 26 2019 Phase 2
NCT03463733 Recruiting Drug: Hydroxyurea|Drug: Temozolomide Glioma|Glioblastoma M.E. van Linde|Massachusetts General Hospital|VU University Medical Center March 2 2018 Phase 1
NCT02507232 Terminated Device: NovoTTF-200A|Drug: Temozolomide Glioma Santosh Kesari|NovoCure Ltd.|John Wayne Cancer Institute April 17 2017 Early Phase 1
NCT02446704 Active not recruiting Drug: Olaparib|Drug: Temozolomide Small Cell Lung Cancer Massachusetts General Hospital|AstraZeneca September 2015 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide (CCRG 81045) | Temozolomide (CCRG 81045) ic50 | Temozolomide (CCRG 81045) price | Temozolomide (CCRG 81045) cost | Temozolomide (CCRG 81045) solubility dmso | Temozolomide (CCRG 81045) purchase | Temozolomide (CCRG 81045) manufacturer | Temozolomide (CCRG 81045) research buy | Temozolomide (CCRG 81045) order | Temozolomide (CCRG 81045) mouse | Temozolomide (CCRG 81045) chemical structure | Temozolomide (CCRG 81045) mw | Temozolomide (CCRG 81045) molecular weight | Temozolomide (CCRG 81045) datasheet | Temozolomide (CCRG 81045) supplier | Temozolomide (CCRG 81045) in vitro | Temozolomide (CCRG 81045) cell line | Temozolomide (CCRG 81045) concentration | Temozolomide (CCRG 81045) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID